CDK4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
2 Views
administrator
07/03/23
Cynthia X. Ma, MD, PhD, Washington University School of Medicine, St. Louis, MI, updates us on recent understanding of potential resistance mechanisms to CDK4/6 inhibitors and therapeutic strategies for hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
-
Category
Show more
Facebook Comments
No comments found